Sensitive Clinical Marker Defined for Ulcerative Colitis Evolution
|
By LabMedica International staff writers Posted on 20 Sep 2016 |
|
Image: The semi-quantitative Calprotectin 50 + 200 combo card test (Photo courtesy of CerTest Biotec).
The two main subtypes of inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC) are characterized by episodes of inflammatory activity and remission and determination of disease activity remains challenging, with most clinical scores correlating poorly with the inflammatory state.
Treatment of IBD patients has recently shifted from controlling symptoms to promoting endoscopic mucosal healing or deep remission and treatment promoting mucosal healing can slow the progression of the disease. In this context, laboratory biomarkers have gained importance in evaluating and predicting the response to therapy.
Scientists at the University of Chile (Santiago, Chile) prospectively recruited 26 patients grouped according to an endoscopic score and therapy response. Colonoscopic biopsies were collected at baseline and six months or when patients showed clinical activity. The protocol was reinitiated in patients requiring rescue therapy. Blood and stool were collected at baseline, one, three, six and 12 months.
Serum and intestinal ST2 (Interleukin 1 receptor-like 1) concentrations, as well as serum interleukin -33 (IL-33) levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit for human ST2 or IL-33 (DuoSet, R&D Systems, Minneapolis, MN, USA). The ST2 detection assay is stable over time, with a detection limit of 20 pg/mL, while the IL-33 detection assay is less stable over time, with a detection limit of 23.4 pg/mL. The supernatant from the fecal samples were processed for the rapid semi-quantitative test Calprotectin 50+200 (CerTest Biotec S.L., Zaragoza, Spain). Mucosal ST2 detection was performed by immunofluorescence and the images captured using an Olympus confocal laser scanning biological microscope FV10i (Olympus America Inc., Melville, NY, USA).
The team reported that follow-up was completed in 24 patients. The statistically significant median and range of soluble sST2 levels varied from 173.5 pg/mL (136.6–274.0) to 86.5 pg/mL (54.6–133.2) in responders and 336.3 pg/mL (211.0–403.2) to 385.3 pg/mL (283.4–517.3) in non-responders at baseline and six months respectively. Soluble sST2 levels correlated with Mayo clinical and endoscopic subscore, mucosal ST2 and fecal calprotectin (FC) and showed a trend similar to that of FC in responders. Non-responders revealed an increased ST2 content, restricted to the lamina propria’s cellular infiltrate.
The authors concluded that during the follow-up, serial ST2 measurements decreased in those patients with a reduced endoscopic index at six months, indicating a positive response to therapy. In those patients, FC levels were also significantly decreased in direct correlation to sST2 levels. The accuracy of sST2 in endoscopic detection of UC strongly suggests its usefulness in monitoring relapse and outcome, as well as in identifying patients likely to benefit from a particular treatment. The study was published on August 28, 2016, in the journal BMC Gastroenterology.
Related Links:
University of Chile
R&D Systems
CerTest Biotec
Olympus America
Treatment of IBD patients has recently shifted from controlling symptoms to promoting endoscopic mucosal healing or deep remission and treatment promoting mucosal healing can slow the progression of the disease. In this context, laboratory biomarkers have gained importance in evaluating and predicting the response to therapy.
Scientists at the University of Chile (Santiago, Chile) prospectively recruited 26 patients grouped according to an endoscopic score and therapy response. Colonoscopic biopsies were collected at baseline and six months or when patients showed clinical activity. The protocol was reinitiated in patients requiring rescue therapy. Blood and stool were collected at baseline, one, three, six and 12 months.
Serum and intestinal ST2 (Interleukin 1 receptor-like 1) concentrations, as well as serum interleukin -33 (IL-33) levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit for human ST2 or IL-33 (DuoSet, R&D Systems, Minneapolis, MN, USA). The ST2 detection assay is stable over time, with a detection limit of 20 pg/mL, while the IL-33 detection assay is less stable over time, with a detection limit of 23.4 pg/mL. The supernatant from the fecal samples were processed for the rapid semi-quantitative test Calprotectin 50+200 (CerTest Biotec S.L., Zaragoza, Spain). Mucosal ST2 detection was performed by immunofluorescence and the images captured using an Olympus confocal laser scanning biological microscope FV10i (Olympus America Inc., Melville, NY, USA).
The team reported that follow-up was completed in 24 patients. The statistically significant median and range of soluble sST2 levels varied from 173.5 pg/mL (136.6–274.0) to 86.5 pg/mL (54.6–133.2) in responders and 336.3 pg/mL (211.0–403.2) to 385.3 pg/mL (283.4–517.3) in non-responders at baseline and six months respectively. Soluble sST2 levels correlated with Mayo clinical and endoscopic subscore, mucosal ST2 and fecal calprotectin (FC) and showed a trend similar to that of FC in responders. Non-responders revealed an increased ST2 content, restricted to the lamina propria’s cellular infiltrate.
The authors concluded that during the follow-up, serial ST2 measurements decreased in those patients with a reduced endoscopic index at six months, indicating a positive response to therapy. In those patients, FC levels were also significantly decreased in direct correlation to sST2 levels. The accuracy of sST2 in endoscopic detection of UC strongly suggests its usefulness in monitoring relapse and outcome, as well as in identifying patients likely to benefit from a particular treatment. The study was published on August 28, 2016, in the journal BMC Gastroenterology.
Related Links:
University of Chile
R&D Systems
CerTest Biotec
Olympus America
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Capillary Blood Collection Tube
IMPROMINI M3
Urine Chemistry Control
Dropper Urine Chemistry Control
Latest Immunology News
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more
Molecular Diagnostics
view channel
Novel Liquid Biopsy Technology to Advance Cancer Diagnostics
Liquid biopsies are increasingly replacing tissue biopsies in cancer care, offering a faster, minimally invasive way to assess tumor genetics from blood samples. However, current liquid biopsy methods... Read more
POC Oral Fluid Test Diagnoses HIV Infection in 20 Minutes
Timely and accurate HIV diagnosis remains a major challenge in many parts of the world, particularly in resource-constrained settings where laboratory infrastructure and trained personnel are limited.... Read more
Hematology
view channel
AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
Alpha thalassemia affects millions of people worldwide and is especially common in regions such as Southeast Asia, where carrier rates can reach extremely high levels. While the condition can have significant... Read more
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Microbiology
view channel
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read more
New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
Antibiotic resistance is rising worldwide, threatening the effectiveness of treatments for major infectious diseases, including tuberculosis (TB). Resistance to key TB drugs, such as bedaquiline, is of... Read more
Pathology
view channel
Intraoperative Tumor Histology to Improve Cancer Surgeries
Surgical removal of cancer remains the first-line treatment for many tumors, but ensuring that all cancerous tissue is removed while preserving healthy tissue is a major challenge. Surgeons currently rely... Read more
Rapid Stool Test Could Help Pinpoint IBD Diagnosis
Inflammatory bowel disease (IBD) is a chronic condition in which the immune system mistakenly attacks the digestive tract, causing persistent gut inflammation. Diagnosis and disease monitoring often depend... Read more
AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Technology
view channel
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read more
Industry
view channel
WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
World Health Expo (WHX) Labs in Dubai (formerly Medlab Middle East), which will be held at Dubai World Trade Centre from 10-13 February, will address the growing global threat of antimicrobial resistance... Read more
